Clinical Trials
9 trialsNCT02379416 2026-06-01
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04449549 2026-05-22
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05554380 2026-05-22
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05554341 2026-05-14
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03907475 2026-05-13
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT02317874 2023-08-29
Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003558 2013-08-07
Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00972205 2012-07-19
Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT00001387 2008-03-04
Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed